Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial

OBJECTIVE: To evaluate the efficacy and safety of oral levosimendan in patients with amyotrophic lateral sclerosis (ALS). This phase II, randomised, double-blind, placebo-controlled, crossover, three-period study with 6 months open-label follow-up enrolled adults with ALS and sitting slow vital capa...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Neurol Neurosurg Psychiatry
Autors principals: Al-Chalabi, Ammar, Shaw, Pamela, Leigh, P Nigel, van den Berg, Leonard, Hardiman, Orla, Ludolph, Albert, Aho, Valtteri V, Sarapohja, Toni, Kuoppamäki, Mikko
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2019
Matèries:
Neuromuscular
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6817985/
https://ncbi.nlm.nih.gov/pubmed/31315908
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jnnp-2018-320288
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars